Global Anti-HER2 Therapy Market Growth (Status and Outlook) 2023-2029

Global Anti-HER2 Therapy Market Growth (Status and Outlook) 2023-2029

Anti-HER2 Therapy is a class of medicines used to treat all stages of HER2-positive breast cancer and certain HER2-low breast cancers.In HER2-positive breast cancer, the HER2 (human epidermal growth factor receptor 2) gene doesn’t work correctly and makes too many copies of itself. These extra HER2 genes make too many proteins known as HER2 receptors.Anti-HER2 medicines attach to the HER2 receptor proteins on the surface of breast cancer cells.Anti-HER2 medicines work by blocking the HER2 receptors from receiving the growth signals in HER2-positive breast cancer. By blocking the growth signals, anti-HER2 medicines can slow or stop the growth of HER2-positive and HER2-low breast cancer. Anti-HER2 medicines only work on HER2-positive and HER2-low breast cancer. They do not work on HER2-negative breast cancer.

LPI (LP Information)' newest research report, the “Anti-HER2 Therapy Industry Forecast” looks at past sales and reviews total world Anti-HER2 Therapy sales in 2022, providing a comprehensive analysis by region and market sector of projected Anti-HER2 Therapy sales for 2023 through 2029. With Anti-HER2 Therapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Anti-HER2 Therapy industry.

This Insight Report provides a comprehensive analysis of the global Anti-HER2 Therapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Anti-HER2 Therapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Anti-HER2 Therapy market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Anti-HER2 Therapy and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Anti-HER2 Therapy.

The global Anti-HER2 Therapy market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Anti-HER2 Therapy is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Anti-HER2 Therapy is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Anti-HER2 Therapy is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Anti-HER2 Therapy players cover GlaxoSmithKline, Bayer, Abbott, AbbVie, Pfizer, Sanofi, Merck, Glenmark Pharmaceuticals and Roche, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Anti-HER2 Therapy market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Anti-HER2 Monoclonal Antibodies
Antibody-Drug Conjugate
Kinase Inhibitors

Segmentation by application
Online Pharmacy
Retail Pharmacy
Medical Clinics

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
GlaxoSmithKline
Bayer
Abbott
AbbVie
Pfizer
Sanofi
Merck
Glenmark Pharmaceuticals
Roche
Novartis
Astra Zeneca
Daiichi Sankyo
Celltrion
Teva
Biocon
Viatris

Please note: The report will take approximately 2 business days to prepare and deliver.